Clinical Trials Logo

Clinical Trial Summary

The objective of the implementation pilot is to assess the practicality of introducing a perioperative immunonutrition protocol into a hospital environment as well as a true measure of impact on the rate of surgical site infection (SSI).


Clinical Trial Description

Postoperative infectious complications are independently associated with increased hospital length of stay (LOS) and cost, and contribute to significant inpatient morbidity. Despite recent advances in surgical techniques and perioperative management, the rate of postoperative infectious complications remains high with 54% of all hospital-acquired-infections occurring in high-risk surgical populations.2 Poor nutritional status along with surgical stress predisposes patients to postoperative complications and immune depression. Research is now demonstrating the importance of additional perioperative nutritional support through the use of enteral and parenteral feeds in high-risk patients, with a specific focus on the role of immunonutrition. Immunonutrition substrates have been found to modulate postsurgical immuno-depression and inflammatory responses and positively impact patient outcomes. Immunonutrition is defined as a solution that contains nutrients such as arginine, omega fatty acids, and protein. Arginine deficiency after surgical stress was first reported over 30 years ago, and recent studies have demonstrated that the perioperative use of arginine-supplemented diets have the ability to decrease the rate of postoperative infection. Arginine is an amino acid that is synthesized in the body but not in high enough concentration to support metabolic needs during periods of stress, such as surgery. While under stress, arginine is the primary fuel source for T-cells and helps maintain immune function and decrease the risk of infection. Th1 induced macrophages also use arginine for many of their immune functions. In addition, omega fatty acids, such as n-6 and n-3, are derived from fish oil and have been shown to attenuate the production of inflammatory compounds and ultimately reduce the cytotoxicity of inflammatory cells. This role that omega fatty acids play in the resolution of inflammation results in enhanced wound healing and improved lymphocyte function. Finally, whey protein substrates have great potential to be used effectively to support post-surgery anabolism. Whey proteins are of high quality, have proved to be effective in modulating muscle protein synthesis, and are a convenient way to supplement protein needs in malnourished patients. Whey proteins also have immuno-modulating properties, including biosynthesis of antioxidant glutathione, which could attenuate the catabolic effects of surgery and spare protein. These ingredients have been shown to work synergistically and are associated with significantly better overall and recurrence-free survival. Each element works towards improving the immune response through modulation of excessive inflammatory responses and replenishing depleted nutrients when the body is in a state of surgical stress.13 The HHS implementation pilot will provide preoperative patients with EMN's immunonutrition formula, INergy-FLD®. INergy-FLD® is an immune-modulating solution that contains whey protein isolate, refined fish oil with omega 6 fatty acids, antioxidants such as vitamins A, C, D and E, and has an elevated amino acid concentration with 4.2 grams of L-Arginine per serving. It has a natural citrus flavor, low sugar and a trace of lactose, and therefore can be tolerated by patients who are lactose intolerant. INergy-FLD® is categorized under Health Canada as a formulated liquid diet (FLD). INergy-FLD® complies with the detailed and explicit compositional and labeling requirements of an FLD supplement as well as providing complete directions for preparation and the use of the food product (Food Category: CFIA) Patient reported consumption diaries will be used to track the consumption of INergy-FLD® by patients in the perioperative period, and patient feedback will be sought on experience and barriers in implementation of this regimen. In order to track the impact of INergy-FLD® on the rate of postoperative infectious complications, HHS will rely on the NSQIP patient-outcome audit system. According to two new studies presented by researchers from the American College of Surgeons (ACS), NSQIP provides more accurate data than administrative data for driving surgical quality improvement. NSQIP codes are standardized, very specific, and can identify the primary reason for readmission. Other advantages of NSQIP include the detail of preoperative risk variables collected by the database, allowing for a more robust risk-adjusted analysis. Using this database available at HHS, EMN will be able to accurately analyze the impact of INergy-FLD® immunonutrition on surgical patient outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04057092
Study type Interventional
Source Hamilton Health Sciences Corporation
Contact
Status Completed
Phase N/A
Start date August 1, 2018
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04096885 - The Inselspital Surgical Cohort Study
Terminated NCT03820648 - Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy N/A
Completed NCT04067843 - Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study N/A
Terminated NCT04042077 - Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections Phase 3
Completed NCT05841576 - Anaesthetic Management Guided by COMET Measurements N/A
Withdrawn NCT05338281 - NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT01697748 - Prospective Study on Cesarean Wound Outcomes N/A
Terminated NCT01789697 - Text Message Study N/A
Recruiting NCT05966961 - Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery
Recruiting NCT05077592 - Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections Phase 4
Recruiting NCT05763602 - PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study) Phase 4
Recruiting NCT05502380 - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery Phase 3
Recruiting NCT03221023 - Intrawound Vancomycin Prophylaxis for Neural Stimulator Phase 2/Phase 3
Completed NCT03257202 - Topical Treatment and Prevalence of P. Acnes Phase 2
Completed NCT06154720 - Surgical Site Infection After Episiotomy Repair Related to Routine Use of Antibiotic Prophylaxis in Low-Risk Population
Not yet recruiting NCT04820075 - Efficacy of an Intervention to Improve the Preoperative Shower in Scheduled Surgery N/A
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Not yet recruiting NCT04496180 - Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy N/A
Recruiting NCT04676841 - Wound Contamination During Orthopaedic Surgery